Janney Montgomery Scott LLC Invests $402,000 in Haemonetics Co. (NYSE:HAE)

Janney Montgomery Scott LLC acquired a new stake in Haemonetics Co. (NYSE:HAE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,147 shares of the medical instruments supplier's stock, valued at approximately $402,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its holdings in Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock valued at $92,000 after buying an additional 632 shares during the period. iSAM Funds UK Ltd purchased a new stake in Haemonetics during the third quarter worth about $204,000. CWC Advisors LLC. purchased a new stake in Haemonetics during the third quarter worth about $231,000. Versor Investments LP increased its stake in Haemonetics by 9.1% during the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier's stock worth $289,000 after purchasing an additional 300 shares during the period. Finally, Verdence Capital Advisors LLC purchased a new stake in Haemonetics during the third quarter worth about $302,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HAE. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an "overweight" rating and a $116.00 price target on the stock. Raymond James reiterated a "strong-buy" rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Barrington Research cut their price target on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. StockNews.com upgraded shares of Haemonetics from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Finally, JMP Securities lowered their price objective on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $101.67.

Haemonetics Stock Up 0.3 %

HAE traded up $0.18 on Friday, reaching $62.47. The company's stock had a trading volume of 1,333,274 shares, compared to its average volume of 1,042,682. The stock has a 50 day moving average of $74.55 and a two-hundred day moving average of $77.58. The company has a quick ratio of 2.09, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of 24.59, a P/E/G ratio of 0.98 and a beta of 0.39. Haemonetics Co. has a fifty-two week low of $58.80 and a fifty-two week high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, analysts forecast that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.